Biopharmaceutical
Pharmaceutical
Health

Esperion Therapeutics

$50.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-0.20%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ESPR and other stocks, options, ETFs, and crypto commission-free!

About

Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Read More The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Employees
76
Headquarters
Ann Arbor, Michigan
Founded
1998
Market Cap
1.37B
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
669.42K
High Today
$50.97
Low Today
$49.92
Open Price
$50.55
Volume
73.45K
52 Week High
$60.99
52 Week Low
$35.80

Collections

Biopharmaceutical
Pharmaceutical
Health
Research And Development
Therapy
Biotechnology
Medical
Technology

News

Yahoo FinanceMay 10

Esperion to Participate in Upcoming Investor Conferences

ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: Bank of America Merrill Lynch Healthcare Conference 2019 in Las Vegas on Tuesday, May 14, 2019 at 6:55 p.m. E.T. in Las Vegas on Tuesday, May 14, 2019 at 6:55 p.m. E.T. UBS Global Healthcare Conference in New York on Monday, May 20, 2019 at 9:30 a.m. E.T. A live audio webcast of the UBS event can be accessed on th...

52
Yahoo FinanceMay 9

Esperion Gets a Go-Ahead from the FDA

Esperion Therapeutics (ESPR) has reported that the FDA has accepted both New Drug Applications for bempedoic acid and the bempedoic acid/ezetimibe combination tablet for filing and regulatory review, asserts John McCamant, biotech expert and editor of The Medical Technology Stock Letter.

85
NasdaqMay 8

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates

Esperion Therapeutics (ESPR) came out with quarterly earnings of $3.07 per share, beating the Zacks Consensus Estimate of $1.32 per share.

37

Earnings

-$2.24
-$0.47
$1.30
$3.07
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.